Morgan Stanley Cns Pharmaceuticals, Inc. Transaction History

Morgan Stanley

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.26 - $1.05 $1,430 - $5,775	-5,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.7 - $1.54 $9 - $20	-13 Reduced 0.24%	5,500 $4,000
Q3 2021 Nov 15, 2021	BUY	$1.4 - $1.98 $7,718 - $10,915	5,513 New	5,513 $8,000

100

Ticker CNSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,032,500
Market Cap $5.2M
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme....

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.